A potential treatment for Alzheimer's disease

( the drug with Transition Therapeutics )

PleaseHelpSupport Alzheimer's Research Today!
Your Alzheimer's donation will help billionslive without it. Donate online now

Pharmaceutical company Elan has said it has modified clinical trials of a potential treatment for Alzheimer's disease after the deaths of nine patients receiving high doses of the trial drug. The clinical trials were taking place in the US. Elan says that no direct relationship between the deaths and taking high doses of the ELND005 drug has been established.

Elan was testing the drug with Transition Therapeutics, with whom it has a commercialisation agreement. Elan and Transition says the nine deaths were in two groups of patients receiving 2000mgs and 4000mgs of the drug daily in two doses a day. A study involving patients receiving 250mgs twice daily and also for a placebo is to continue.

A total of 353 patients were involved in the trials and the decision to drop the trials was agreed with the US Independent Safety Monitoring Committee. Brokers say a high number of such trials end in failure while little of Elan's share value would be dependant on a successful outcome of these Alzheimer Drug trials. ...http://www.rte.ie

DHA revisions offer hope to health claim rejections

The affirmation that the omega-3 DHA can benefit cognitive and eye health offers hope to previously rejected claims, says a European Commission representative. ... ...http://www.nutraingredients.com/

Беларусь ТВ

Posted YVN